Dipna Pharmachem Ltd (DPL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Dipna Pharmachem Ltd on NSE and BSE, with an AI summary of each filing.
Integrated Filing
Others (Uncategorized) · 04 Nov 2026, 11:21 pm
Dipna Pharmachem Reports Q1 FY27 Standalone Financial Results Dipna Pharmachem reported standalone total income of Rs 2,379.06 lakhs for the quarter ended 30th Jun'26, rising 28.60% YoY from Rs 1,850.04 lakhs in 30th Jun'25 and up sharply QoQ from Rs 205.03 lakhs. Net profit declined 30.87% YoY to Rs 39.42 lakhs compared to Rs 57.02 lakhs in 30th Jun'25, but grew 120.72% QoQ from Rs 17.86 lakhs. Basic and diluted EPS stood at Rs 0.15 versus Rs 0.24 YoY. Total expenses reached Rs 2,326.64 lakhs, primarily driven by purchase of stock-in-trade at Rs 1,890.28 lakhs.
Outcome of Board Meeting held today i.e. 4th November, 2026
Financial Result · 04 Nov 2026, 11:17 pm
Dipna Pharmachem Reports Q1 FY27 Results With Total Income Up YoY Dipna Pharmachem reported standalone total income of ₹2,379.06 lakh for the quarter ended 30th Jun'26, up 28.60% YoY from ₹1,850.04 lakh in 30th Jun'25 and up significantly QoQ from ₹205.03 lakh in 31st Mar'26. Revenue from operations reached ₹2,033.03 lakh alongside other operating income of ₹346.03 lakh. Net profit stood at ₹39.42 lakh, declining 30.87% YoY from ₹57.02 lakh but recovering 120.72% QoQ from ₹17.86 lakh. Basic and diluted EPS for the quarter was ₹0.15 compared to ₹0.24 YoY and ₹0.07 QoQ.
Outcome of Board Meeting held today i.e. 4th November, 2026
Outcome · 04 Nov 2026, 11:11 pm
Dipna Pharmachem Reports Q1 Financial Results for Period Ended 30th Jun'26 Dipna Pharmachem Limited reported total income of Rs 2,379.06 lakh for the quarter ended 30th Jun'26, up 28.60% YoY from Rs 1,850.04 lakh in Q1 FY26 and surging QoQ from Rs 205.03 lakh in Q4 FY26. Net profit stood at Rs 39.42 lakh, declining 30.87% YoY compared to Rs 57.02 lakh in the prior-year period, but recovering from Rs 17.86 lakh in the preceding quarter. Basic and diluted EPS were Rs 0.15 versus Rs 0.24 YoY. Total expenses increased to Rs 2,326.64 lakh.
Reconstitution of the Committee
Others (Uncategorized) · 04 Nov 2026, 1:39 am
Dipna Pharmachem Appoints Independent Directors and Reconstitutes Key Board Committees Dipna Pharmachem Limited's Board of Directors approved the appointment of Mr. Hiteshkumar Shankarlal Parmar and Mr. Swetal Nalinbhai Shah as Additional Non-Executive and Independent Directors, effective 3rd Nov'26. Consequently, the company reconstituted its Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee. Mr. Parmar serves as Chairperson across all three committees, joined by Mr. Shah and Mrs. Dipna Keyur Shah as members. Both newly appointed directors are commerce graduates with business management expertise and are unrelated to any existing board directors.
Outcome and Intimation Under Regulation 30 of SEBI (LODR) Regulations, 2015
Change in Management · 04 Nov 2026, 1:37 am
Dipna Pharmachem Appoints Independent Directors and Reconstitutes Key Board Committees Dipna Pharmachem Limited's Board of Directors approved the appointments of Mr. Hiteshkumar Shankarlal Parmar and Mr. Swetal Nalinbhai Shah as Additional Non-Executive and Independent Directors, effective 3rd Nov'26. Consequently, the Board reconstituted the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, each comprising Mr. Parmar as Chairperson, alongside Mr. Shah and Mrs. Dipna Keyur Shah as members. Both newly appointed directors are unrelated to existing board members.
Outcome and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 04 Nov 2026, 1:34 am
Dipna Pharmachem Appoints Independent Directors and Reconstitutes Key Board Committees Dipna Pharmachem Limited's Board of Directors approved the appointments of Mr. Hiteshkumar Shankarlal Parmar and Mr. Swetal Nalinbhai Shah as Additional Non-Executive and Independent Directors, effective 3rd Nov'26. Consequently, the company reconstituted its Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, appointing Mr. Parmar as Chairperson and Mr. Shah alongside Mrs. Dipna Keyur Shah as members across all three committees. Both appointees are commerce graduates with commercial experience and hold no relationships with existing board members.
Dipna Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) ....
Intimation · 01 Nov 2026, 12:20 am
Dipna Pharmachem Schedules Board Meeting on 4th Nov'26 for Q1 Results Dipna Pharmachem Limited has scheduled a meeting of its Board of Directors on 4th Nov'26 at 5:00 PM at its Ahmedabad registered office. Pursuant to Regulation 29(1) of SEBI LODR Regulations, the board will convene inter alia to consider, approve, and take on record the company's unaudited financial results along with the Limited Review Report for the quarter ended 30th Jun'26.
Outcome and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 24 Oct 2026, 10:25 pm
Dipna Pharmachem Board Changes and Committee Reconstitution Dipna Pharmachem announced the appointment of Mr. Nirav Madhusudan Soni as an Additional Non-Executive, Non-Independent Director effective 10th Aug'26. Concurrently, Non-Executive Independent Directors Mr. Jitendra Pradipbhai Parmar and Mr. Manish Shrichand Bachani resigned due to personal reasons, confirming no other material factors. Following these departures, the board reconstituted its Audit, Nomination & Remuneration, and Stakeholders Relationship Committees, appointing Mr. Nirav Madhusudan Soni as Chairperson across all three committees alongside Managing Director Mr. Keyur Shah and Non-Executive Director Mrs. Dipna Keyur Shah.
Announcement under Regulation 30 (LODR) - Resignation of Director
Change in Management · 24 Oct 2026, 10:13 pm
Dipna Pharmachem Announces Board Resignations, New Director Appointment, and Committee Reconstitutions Dipna Pharmachem Limited announced key board changes effective 10th Aug'26 following a board meeting. Independent directors Mr. Jitendra Pradipbhai Parmar and Mr. Manish Shrichand Bachani resigned citing personal reasons, confirming no other material factors. Simultaneously, Mr. Nirav Madhusudan Soni was appointed as an Additional Non-Executive and Non-Independent Director. Consequently, the company reconstituted its Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, appointing Mr. Nirav Madhusudan Soni as Chairperson alongside Managing Director Mr. Keyur Shah and Non-Executive Director Mrs. Dipna Keyur Shah.
Announcement under Regulation 30 (LODR) - Change in Directorate
Change in Management · 24 Oct 2026, 10:07 pm
Dipna Pharmachem Announces Board and Committee Restructuring Dipna Pharmachem Limited appointed Nirav Madhusudan Soni as an Additional Non-Executive, Non-Independent Director effective 10th Aug'26. Concurrently, Independent Directors Jitendra Pradipbhai Parmar and Manish Shrichand Bachani resigned effective 10th Aug'26, citing personal reasons with no other material factors reported. Following these departures, the board reconstituted its Audit, Nomination & Remuneration, and Stakeholders Relationship Committees, naming Nirav Madhusudan Soni as Chairperson alongside Managing Director Keyur Shah and Non-Executive Director Dipna Keyur Shah as members across all three committees.
Outcome and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 24 Oct 2026, 9:58 pm
Dipna Pharmachem Board Approves Key Leadership and Committee Reconstitution Dipna Pharmachem Limited announced that its Board of Directors approved the appointment of Mr. Nirav Madhusudan Soni as an Additional Non-Executive and Non-Independent Director, effective 10th Aug'26. Concurrently, Independent Directors Mr. Jitendra Pradipbhai Parmar and Mr. Manish Shrichand Bachani resigned due to personal reasons, with no other material reasons reported. Consequently, the company reconstituted its Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, appointing Mr. Nirav Madhusudan Soni as Chairperson across all three key board committees.
Appointment of Company Secretary and Compliance Officer
Change in Management · 24 Oct 2026, 12:45 am
Dipna Pharmachem Appoints Shyam Sundar Lohia as Company Secretary and Compliance Officer Dipna Pharmachem Limited's Board of Directors approved the appointment of Mr. Shyam Sundar Lohia (Membership No. A28706) as Company Secretary and Compliance Officer, effective 5th Aug'26. Mr. Lohia is a qualified Company Secretary possessing over 12 years of experience across corporate secretarial functions, regulatory compliances, SEBI and FEMA regulations, corporate governance, and ROC filings. He has no familial relationships with any existing directors of the company.
Outcome and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 24 Oct 2026, 12:33 am
Dipna Pharmachem Appoints Shyam Sundar Lohia as Company Secretary and Compliance Officer Dipna Pharmachem Limited's Board of Directors approved the appointment of Mr. Shyam Sundar Lohia (Membership No: A28706) as Company Secretary and Compliance Officer, effective 5th Aug'26. Mr. Lohia is a qualified Company Secretary with over 12 years of experience spanning corporate secretarial functions, regulatory and FEMA compliance, corporate governance, SEBI regulations, and ROC filings. He has no familial relationships with any of the company's directors.
Submission of Integrated Financials
Others (Uncategorized) · 03 Jul 2026, 2:58 am
Dipna Pharmachem Reports Strong FY26 Growth, Q4 Performance Falters For FY26, Dipna Pharmachem reported a significant 170% YoY increase in Net Profit to ₹263.19 lakhs, with total income growing 3.4% YoY to ₹12,910.87 lakhs. Full-year EPS rose to ₹1.00 from ₹0.41. However, Q4 FY26 performance weakened, with revenue declining 87.3% YoY to ₹202.49 lakhs. Net profit for the quarter fell by 64.4% YoY to ₹17.86 lakhs. The Steel segment contributed significantly to full-year revenue at ₹7,089.14 lakhs, while the Chemicals segment posted an annual loss of ₹512.35 lakhs.
Submission of Statment of Deviation and Variation
Others (Uncategorized) · 03 Jul 2026, 2:55 am
Dipna Pharmachem FY26 Net Profit Soars 170% on Strong Revenue Growth Dipna Pharmachem reported a 170.2% YoY rise in FY26 PAT to ₹263.19 Lakhs, with revenue growing 3.3% YoY to ₹12,908.33 Lakhs. For Q4 FY26, PAT stood at ₹17.86 Lakhs on revenue of ₹202.49 Lakhs. The Board approved the audited financials on 2nd Jul'26. A statement confirmed no deviation in using funds from its preferential issue of convertible warrants. FY26 EPS increased to ₹1.00 from ₹0.41 in FY25. The Chemicals segment contributed 45% of revenue but incurred a loss.
Submission of Financial Results
Financial Result · 03 Jul 2026, 2:52 am
Dipna Pharmachem Reports Strong FY26 Growth, Q4 Revenue Slumps Dipna Pharmachem (BSE: 543594) reported FY26 net profit of ₹263.19 lakhs, a 170% YoY increase, on revenue of ₹12,910.87 lakhs, up 3.3% YoY. The performance was driven by the Steel segment, which offset a significant loss in the Chemicals segment. However, Q4 FY26 results were weak, with revenue plummeting 87.1% YoY to ₹205.03 lakhs and net profit dropping 64.4% YoY to ₹17.86 lakhs. Full-year EPS rose to ₹1.00 from ₹0.41 in FY25, while Q4 EPS fell to ₹0.07 from ₹0.21.
Outcome of Board Meeting held today i.e. 2nd July, 2026
Outcome · 03 Jul 2026, 2:48 am
Dipna Pharmachem FY26 Results: Net Profit Surges 170% YoY on Higher Revenue Dipna Pharmachem reported FY26 net profit of ₹263.19 Lakh, a 170% YoY increase from ₹97.40 Lakh in FY25. Total income for the year grew 3.3% YoY to ₹12,910.87 Lakh. For Q4FY26, net profit was ₹17.86 Lakh vs. ₹50.13 Lakh in Q4FY25, on revenue of ₹202.49 Lakh, down from ₹1,591.68 Lakh YoY. The Steel segment drove full-year revenue growth, while the Chemicals segment posted a significant loss of ₹512.35 Lakh. The Board approved the audited financials on 2nd Jul'26.
Announcement under Regulation 30 (LODR) - Resignation of Director
Change in Management · 03 Jul 2026, 2:33 am
Dipna Pharmachem: Independent Director Resigns Mr. Nandish Shaileshbhai Jani has resigned as a Non-Executive and Independent Director of Dipna Pharmachem Limited, effective 10th Jun'26. The company filing cites personal reasons for the departure, with confirmation that there are no other material reasons. Mr. Jani also holds Independent Director positions at Magenta Lifecare Limited and AKI India Limited.
Announcement under Regulation 30 (LODR) - Resignation of Director
Change in Management · 03 Jul 2026, 2:26 am
Dipna Pharmachem: Independent Director Parin Bhavsar Resigns Mr. Parin Bhavsar has resigned as a Non-Executive and Independent Director of Dipna Pharmachem Limited, effective 12th May'26. The resignation is attributed to pre-occupancy. Mr. Bhavsar has confirmed there are no other material reasons for his departure. He also holds a directorship at Chandrima Mercantiles Limited and is a member of its Audit, Nomination & Remuneration, and Stakeholders' Relationship committees.
Announcement under Regulation 30 (LODR) - Change in Directorate
Change in Management · 03 Jul 2026, 2:11 am
Dipna Pharmachem Appoints Two Independent Directors and Reconstitutes Board Committees Dipna Pharmachem Limited appointed Mr. Jitendra Pradipbhai Parmar and Mr. Manish Shrichand Bachani as Additional Non-Executive Independent Directors, effective 11th May'26. Concurrently, the company reconstituted its Audit, Nomination and Remuneration, and Stakeholders Relationship committees. Mr. Jitendra Parmar, a Practicing Company Secretary, will now chair all three committees. The appointments aim to strengthen corporate governance and oversight within the company's board structure. These changes follow a Board of Directors meeting held on 11th May'26.
Outcome and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 03 Jul 2026, 2:06 am
Dipna Pharmachem Appoints Two Independent Directors, Reconstitutes Committees Dipna Pharmachem appointed Mr. Jitendra Pradipbhai Parmar and Mr. Manish Shrichand Bachani as Additional Non-Executive and Independent Directors, effective 11th May'26. Concurrently, the Board reconstituted its Audit, Nomination and Remuneration, and Stakeholders Relationship Committees. In all three committees, Mr. Parmar will serve as Chairperson, with Mr. Bachani and Mrs. Dipna Keyur Shah serving as members. The appointments aim to enhance corporate governance and board independence. Both new directors are confirmed to have no relations with existing directors.
Outcome and Intimation for Rescheduling of Board Meeting to 2nd July, 2026
Outcome · 02 Jul 2026, 12:55 am
Dipna Pharmachem Reschedules Board Meeting for FY26 Results Dipna Pharmachem Limited (DPL) has rescheduled its board meeting to 2nd Jul'26 at 4:00 PM, following a meeting held on 1st Jul'26. The agenda is to consider and approve the audited financial results for the half-year and year ended 31st Mar'26, along with the Auditor's Report. The meeting will take place at the company's registered office.
Dipna Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/07/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....
Intimation · 01 Jul 2026, 5:30 am
Dipna Pharmachem Board Meeting on 1st Jul'26 for FY26 Financial Results Dipna Pharmachem Limited has scheduled a Board of Directors meeting for 1st Jul'26 at 4:00 PM. The primary agenda is to consider and approve the audited financial results for the half-year and full-year ended on 31st Mar'26. The board will also review the corresponding Auditor's Report. This meeting is crucial for the official release of the company's annual financial performance data.
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 22 Apr 2026, 8:30 pm
Dipna Pharmachem Board Approves New Secretarial Auditor for FY26 Dipna Pharmachem's Board of Directors approved the appointment of M/s. Jay Pandya & Associates as the Secretarial Auditor for FY26 on 22nd Apr'26. This appointment is subject to shareholder approval, which will be sought via a postal ballot. The remote e-voting for the resolution will be conducted from 23rd Apr'26 to 22nd May'26. The appointment is to comply with the Companies Act, 2013 and SEBI Listing Regulations.
Outcome of the Board meeting and Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 22 Apr 2026, 8:24 pm
Dipna Pharmachem Appoints New Secretarial Auditor for FY26 The Board of Directors on 22nd Apr'26 approved the appointment of M/s. Jay Pandya & Associates as the Secretarial Auditor for FY 2025-26. This appointment is subject to shareholder approval, which will be sought via a postal ballot. The remote e-voting for this resolution will be open from 09:00 A.M. on 23rd Apr'26 until 05:00 P.M. on 22nd May'26. The appointment complies with the Companies Act, 2013 and SEBI Listing Regulations.